# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Jeffrey Stantial maintains Ballys (NYSE:BALY) with a Hold and raises the price target from $11 to $14.
The Company's annual guidance remains unchanged with expectations for 2024 revenues in a range of $2.5 billion to $2.7 bill...
Ballys (NYSE:BALY) reported quarterly losses of $(3.61) per share which missed the analyst consensus estimate of $(1.18) by 205...
Truist Securities analyst Barry Jonas maintains Ballys (NYSE:BALY) with a Buy and raises the price target from $14 to $16.
The special committee of independent and disinterested directors (the "Special Committee") of Bally's Corporation (...
The Board of Directors of Bally's Corporation (NYSE:BALY) today announced that it has formed a special committee of indepen...
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...